Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis
ConclusionsDelayed addition of anti-EGFR mAbs to first-line chemotherapy was not associated with inferior survival or response rates.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Colorectal Cancer | Databases & Libraries | Erbitux